Druggable targets of squamous cell lung cancer.

ABSTRACT: Knowledge of molecular pathogenesis of non-small cell lung cancer has increased remarkably and changed the principles of treatment, especially during the past decade. These advancements have been limited mainly to adenocarcinoma of the lung. Recently, genetic alterations in squamous cell lung cancer (SQCLC) have been detailed and positive results of clinical trials using agents targeting these changes have indicated the potential for improved treatment outcomes for SQCLC.

SUBMITTER: Kim CH 

PROVIDER: S-EPMC3884109 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature